Cantor Fitzgerald analyst Steve Seedhouse raised the firm’s price target on Wave Life Sciences (WVE) to $34 from $12 and keeps an Overweight rating on the shares. The firm updated its model following Wave’s WVE-007 INHBE update, and increases the probability of success for WVE-007 in obesity to 35% from 20%, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE:
- Structure Therapeutics Stock (GPCR) Spikes 102% as Obesity Trial Beats Eli Lilly, Novo Nordisk
- Wave Life Sciences price target raised to $40 from $19 at Canaccord
- Wave Life Sciences price target raised to $29 from $16 at Wells Fargo
- Wave Life Sciences price target raised to $30 from $16 at Citi
- Closing Bell Movers: Toll Brothers slips 4% after Q4 earnings miss